Orchestra BioMed Holdings Inc

Health Sciences Acquisitions Corp. 2 is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on May 25, 2020 and is headquartered in New York, NY.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded on May 25, 2020 and is headquartered in New Hope, PA.

NEW HOPE, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the U.S. Food and Drug Administration (“FDA”) granted approval of an investigational device exemption (“IDE”) to initiate the global pivotal BACKBEAT ( B radyc A rdia pa C ema K er with atrioventricular interval modulation for B lood pr E ssure tre A tmen T ) study evaluating the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™) for treating hypertensive patients who are indicated for a dual-chamber cardiac pacemaker.

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2023 financial results and provided a business update.

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

NEW HOPE, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the U.S. Food and Drug Administration (the “FDA”) granted investigational device exemption (“IDE”) approval with conditions to initiate the Virtue ISR-US pivotal study evaluating the efficacy and safety of Virtue® SAB for the treatment of patients with coronary ISR. Virtue SAB is a novel AngioInfusion balloon for the treatment of artery disease that is designed to enable protected delivery of SirolimusEFR™, a proprietary, investigational, extended release formulation of sirolimus, to the artery during balloon angioplasty without the need for balloon coating or a permanent implant.

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Orchestra BioMed has a collaboration with Medtronic. The company was just added to several Russell indexes.

Why Shares of Orchestra BioMed Holdings Jumped Wednesday

NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that it is set to join the broad-market Russell 3000® Index, the small-cap Russell 2000® Index, and the Russell Microcap® index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens today, June 26, 2023, according to a preliminary list of additions posted May 19, 2023.

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

NEW HOPE, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial results and provided a business update.

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed just went public via a SPAC merger in January. The company has partnerships with Medtronic and Terumo.

Why Shares of Orchestra BioMed Jumped This Week

NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that previously reported data from its BackBeat Cardiac Neuromodulation Therapy™ (CNT™) and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) programs will be featured in upcoming oral presentations at the Cardiovascular Research Technologies (CRT) 2023 Meeting, which is being held in Washington, DC, from February 25 – 28, 2023.

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

News for Orchestra BioMed Holdings Inc Stock (OBIO)